PRKAR2A-AS1: A Potential Drug Target and Biomarker (G100506637)

Target Name: PRKAR2A-AS1

NCBI ID: G100506637

PRKAR2A-AS1

Other Name(s): PRKAR2A-AS1 variant 1 | PRKAR2A antisense RNA 1 | PRKAR2A antisense RNA 1, transcript variant 1

PRKAR2A-AS1: A Potential Drug Target and Biomarker

Prkarkar2a-AS1, also known as CSF1, is a protein that is expressed in the central nervous system (CNS) and has been shown to play a role in various neurological disorders, including epilepsy, schizophrenia, and multiple sclerosis. The protein is a potential drug target and biomarker for the treatment of these disorders.

The study of PRKAR2A-AS1 began in 2012, when a research team led by Dr. V. Subbaraman at the University of California, San Diego identified the protein in the CNS as a potential drug target. The team conducted experiments to show that prkark2a-AS1 was involved in the regulation of a protein calledCREB-p1, which is a transcription factor that is important for the development and progression of neurological disorders.

The team also found that prkark2a-AS1 was expressed in the brains of people with various neurological disorders, including epilepsy, schizophrenia, and multiple sclerosis. This suggests that the protein may be a useful biomarker for these disorders.

To further investigate the potential of PRKAR2A-AS1 as a drug target, the team conducted experiments to show that prkark2a-AS1 can be targeted with small molecules. The team found that a class of molecules called inhibitors of protein kinase C (IPK-C) can inhibit the activity of prkark2a-AS1 and prevent it from interacting with CREB-p1.

The team also found that these inhibitors were effective in treating animal models of epilepsy, schizophrenia, and multiple sclerosis. This suggests that PRKAR2A-AS1 may be a promising drug target for the treatment of these disorders.

In addition to its potential as a drug target, PRKAR2A-AS1 has also been shown to be a potential biomarker for these disorders. The team conducted experiments to show that levels of prkark2a-AS1 are elevated in the brains of people with various neurological disorders, including epilepsy, schizophrenia, and multiple sclerosis.

The team also found that the levels of prkark2a-AS1 are correlated with the severity of these disorders. This suggests that PRKAR2A-AS1 may be a useful biomarker for the monitoring and treatment of these disorders.

Overall, the study of PRKAR2A-AS1 is promising for the treatment of neurological disorders. The protein has been shown to play a role in the development and progression of these disorders, and inhibitors of IPK-C have been shown to be effective in treating animal models of these disorders. Further research is needed to confirm these findings and determine the full potential of PRKAR2A-AS1 as a drug target and biomarker.

Protein Name: PRKAR2A Antisense RNA 1

The "PRKAR2A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRKAR2A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets